Company intelligence / Profile preview

Neurocode Labs

Bellingham, Washington, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

Neurocode Labs is the first laboratory globally to offer the ALZpath Dx pTau217 blood test for clinical use within a CAP-accredited, CLIA-certified facility. Their ALZpath pTau217 assay demonstrates superior accuracy in early-stage Alzheimer’s diagnosis, with an AUC exceeding 0.94—surpassing NIA-AA criteria. The company also offers a comprehensive suite of plasma and CSF biomarker assays for various neurodegenerative and neuroimmunological conditions.

Therapeutic areas: Neurology
Modalities: Diagnostic assayBlood-based biomarker testCell-based assay
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

ALZpath Dx

Commercial

Indications: Alzheimer's disease

Partnerships

University of British Columbia [investor/collaborator]Research collaborations with academic institutions

Beyond the preview

Go deeper on Neurocode Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurocode Labs.

Explore the full profile